Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma
Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in i...
Saved in:
| Published in | Oncology letters Vol. 15; no. 3; pp. 3496 - 3503 |
|---|---|
| Main Authors | , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Greece
Spandidos Publications
01.03.2018
Spandidos Publications UK Ltd D.A. Spandidos |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1792-1074 1792-1082 |
| DOI | 10.3892/ol.2018.7786 |
Cover
| Abstract | Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III-IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I-II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-γ in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III-IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy. |
|---|---|
| AbstractList | Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mono-nuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III-IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I-II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-[gamma] in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III-IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy. Key words: carcinoembryonic antigen-related cell adhesion molecule 1, glioma, T cells, homophilic interactions, immunoregulation, clinical manifestation Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III–IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I–II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-γ in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III–IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy. Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III-IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I-II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-γ in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III-IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy.Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mononuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III-IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I-II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-γ in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III-IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy. Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing immunosuppression. The homophilic interactions of the carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) serve a critical function in immunoregulation. In the present study, the expression levels of CEACAM1 in peripheral blood mono-nuclear cells and tumor-infiltrating lymphocytes (TILs) from patients with gliomas were assessed. Furthermore, associations between CEACAM1 expression and multiple clinicopathological characteristics in patients with gliomas were analyzed. The results of the present study suggested that the expression of CEACAM1 in circulating T cells was markedly increased in patients with gliomas compared with control subjects, and was further increased in TILs. Patients with high-grade gliomas [World Health Organization (WHO) grade III-IV] demonstrated a significantly increased expression of CEACAM1 on T cells compared with those with low-grade gliomas (WHO grade I-II). Furthermore, the expression of CEACAM1 on T cells was negatively correlated with the Karnofsky score and the plasma level of interferon-[gamma] in patients with gliomas. Immunohistochemical analysis revealed that the expression levels of CEACAM1 in high-grade glioma tissues (WHO grade III-IV) were increased compared with the expression levels in the controls, and were associated with the expression of CEACAM1 in TILs. In summary, the results of the present study indicate that homophilic interactions of CEACAM1 may participate in the progression and development of gliomas through their negative regulatory effects on T cells. Thus, CEACAM1 may be a promising candidate for targeted glioma immunotherapy. |
| Audience | Academic |
| Author | Su, Wen Fan, Yimin Liu, Xiaodong Zhuang, Guotao Duan, Yijun Wang, Hongqin Li, Jinhu Wang, Yazhou |
| AuthorAffiliation | 2 Department of Immunology, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China 3 Department of Neurosurgery, People's Hospital of Zhengzhou, Zhengzhou, Henan 450053, P.R. China 1 Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China 4 Department of Neurosurgery, The Fifth People's Hospital of Datong, Datong, Shanxi 037006, P.R. China |
| AuthorAffiliation_xml | – name: 1 Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China – name: 2 Department of Immunology, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China – name: 4 Department of Neurosurgery, The Fifth People's Hospital of Datong, Datong, Shanxi 037006, P.R. China – name: 3 Department of Neurosurgery, People's Hospital of Zhengzhou, Zhengzhou, Henan 450053, P.R. China |
| Author_xml | – sequence: 1 givenname: Jinhu surname: Li fullname: Li, Jinhu organization: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China – sequence: 2 givenname: Xiaodong surname: Liu fullname: Liu, Xiaodong organization: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China – sequence: 3 givenname: Yijun surname: Duan fullname: Duan, Yijun organization: Department of Immunology, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China – sequence: 4 givenname: Hongqin surname: Wang fullname: Wang, Hongqin organization: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China – sequence: 5 givenname: Wen surname: Su fullname: Su, Wen organization: Department of Immunology, Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi 030013, P.R. China – sequence: 6 givenname: Yazhou surname: Wang fullname: Wang, Yazhou organization: Department of Neurosurgery, People's Hospital of Zhengzhou, Zhengzhou, Henan 450053, P.R. China – sequence: 7 givenname: Guotao surname: Zhuang fullname: Zhuang, Guotao organization: Department of Neurosurgery, The Fifth People's Hospital of Datong, Datong, Shanxi 037006, P.R. China – sequence: 8 givenname: Yimin surname: Fan fullname: Fan, Yimin organization: Department of Neurosurgery, The First Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, P.R. China |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29467871$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkk1v1DAQhiNUREvpjTOyhIQ4kMV2Ese-IK0qvqRKXOBsOc4kceXYi-0A_Q38aRy2LN2q9sGW55l3PB9PixPnHRTFc4I3FRf0rbcbignftC1nj4oz0gpaEszpyeHe1qfFRYzXOK-GEc7Zk-KUipq1vCVnxe9t53yYlUXwaxcgRuMd8gPSJujFqmTciJTrUVpmH0rjBmNT2D9rFbRxHuYu3HhndOaSGcGVAbIj9EiDtUj1E_wVnb2FLAmIIOPQLmuASxH9NGlCozV-Vs-Kx4OyES5uz_Pi24f3Xy8_lVdfPn6-3F6VuiE4lV3PK9GAboFWgraC0Z6xDoOuuw7XjRC60k01QMfYMHR9o1pWk16D6lTfioFU58W7ve5u6WbIFpdTsnIXzKzCjfTKyGOLM5Mc_Q_ZrMG4yAKvbwWC_75ATHI2cc1WOfBLlBTnslMsaprRl_fQa78El9PLFKkJFwxX_6lRWZC5yj7H1auo3DZVhUVTNyu1eYDKu4fZ6DwYuTlw7PDqjsMEyqYperuk3I94DL64W5FDKf7NSQbe7AEdfIwBhgNCsFwnUXq7JsTlOokZp_dwbZJaw-YfG_uw0x-NwuMQ |
| CitedBy_id | crossref_primary_10_3389_fimmu_2023_1295232 crossref_primary_10_1080_2162402X_2019_1581531 crossref_primary_10_1007_s12672_023_00638_x |
| Cites_doi | 10.3390/cancers5041379 10.1016/j.jpainsymman.2013.05.006 10.1089/dna.2013.2306 10.1007/s11060-012-1021-2 10.18632/oncotarget.7379 10.1155/2016/4683607 10.2217/cns.12.6 10.1186/1476-4598-13-132 10.1158/0008-5472.CAN-12-1187 10.1038/nature13848 10.1038/nri1864 10.4049/jimmunol.177.9.6062 10.1002/eji.201242676 10.1158/1535-7163.MCT-11-0526 10.18632/oncotarget.9871 10.1007/s00401-007-0278-6 10.1016/j.humpath.2016.04.022 10.1371/journal.pone.0089991 10.1084/jem.20102575 10.1158/1078-0432.CCR-14-0514 10.4049/jimmunol.168.6.2803 10.1016/j.yexcr.2013.02.020 10.1093/neuonc/nop066 10.1097/CJI.0000000000000100 10.3892/or.2014.3474 10.1056/NEJMoa043330 10.1158/1078-0432.CCR-11-0880 10.1200/JCO.2016.34.15_suppl.3044 10.3892/ol.2016.4142 10.1245/s10434-013-3460-1 10.1126/science.aaa8172 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2018 Spandidos Publications Copyright Spandidos Publications UK Ltd. 2018 Copyright: © Li et al. 2018 |
| Copyright_xml | – notice: COPYRIGHT 2018 Spandidos Publications – notice: Copyright Spandidos Publications UK Ltd. 2018 – notice: Copyright: © Li et al. 2018 |
| DBID | AAYXX CITATION NPM 3V. 7X7 7XB 8FI 8FJ 8FK ABUWG AFKRA AN0 BENPR CCPQU FYUFA GHDGH K9. M0S PHGZM PHGZT PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM |
| DOI | 10.3892/ol.2018.7786 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland British Nursing Database (Proquest) ProQuest Central ProQuest One ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Central Premium ProQuest One Academic (New) ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef PubMed ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) British Nursing Index with Full Text ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection ProQuest One Health & Nursing Health Research Premium Collection (Alumni) ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) ProQuest Central (New) ProQuest One Academic ProQuest Central (Alumni) ProQuest One Academic (New) MEDLINE - Academic |
| DatabaseTitleList | ProQuest One Academic Middle East (New) MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X7 name: Health & Medical Collection url: https://search.proquest.com/healthcomplete sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1792-1082 |
| EndPage | 3503 |
| ExternalDocumentID | PMC5796289 A533095453 29467871 10_3892_ol_2018_7786 |
| Genre | Journal Article |
| GeographicLocations | United States--US China |
| GeographicLocations_xml | – name: China – name: United States--US |
| GroupedDBID | --- 0R~ 53G 7X7 8FI 8FJ AAKDD AAYXX ABDBF ABJNI ABUWG ACGFS ACUHS ADBBV AENEX AFKRA AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BENPR BNQBC BPHCQ BVXVI C45 CCPQU CITATION EBD EBS EJD ESX F5P FYUFA H13 HMCUK HUR HZ~ IAO IHR IHW IPNFZ ITC O9- OK1 OVD PHGZM PHGZT PQQKQ PROAC RIG RPM TEORI UKHRP W2D 3V. NPM PMFND 7XB 8FK K9. PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c510t-bd8395ec7e23927962d66b0ec4bb04599c3c53feb66ffbd5a7641dceabad79f13 |
| IEDL.DBID | 7X7 |
| ISSN | 1792-1074 |
| IngestDate | Thu Aug 21 13:55:30 EDT 2025 Fri Sep 05 09:38:32 EDT 2025 Fri Jul 25 19:59:41 EDT 2025 Tue Jun 17 21:34:02 EDT 2025 Tue Jun 10 20:13:17 EDT 2025 Thu May 22 21:23:22 EDT 2025 Wed Feb 19 02:42:20 EST 2025 Thu Apr 24 23:07:02 EDT 2025 Tue Jul 01 01:58:36 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 3 |
| Keywords | carcinoembryonic antigen-related cell adhesion molecule 1 glioma immunoregulation T cells homophilic interactions clinical manifestation |
| Language | English |
| License | This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c510t-bd8395ec7e23927962d66b0ec4bb04599c3c53feb66ffbd5a7641dceabad79f13 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC5796289 |
| PMID | 29467871 |
| PQID | 2014189603 |
| PQPubID | 2044954 |
| PageCount | 8 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_5796289 proquest_miscellaneous_2007420942 proquest_journals_2014189603 gale_infotracmisc_A533095453 gale_infotracacademiconefile_A533095453 gale_healthsolutions_A533095453 pubmed_primary_29467871 crossref_primary_10_3892_ol_2018_7786 crossref_citationtrail_10_3892_ol_2018_7786 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2018-03-01 |
| PublicationDateYYYYMMDD | 2018-03-01 |
| PublicationDate_xml | – month: 03 year: 2018 text: 2018-03-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | Greece |
| PublicationPlace_xml | – name: Greece – name: Athens |
| PublicationTitle | Oncology letters |
| PublicationTitleAlternate | Oncol Lett |
| PublicationYear | 2018 |
| Publisher | Spandidos Publications Spandidos Publications UK Ltd D.A. Spandidos |
| Publisher_xml | – name: Spandidos Publications – name: Spandidos Publications UK Ltd – name: D.A. Spandidos |
| References | Lemke (key20200714002512_b18-ol-0-0-7786) 2012; 18 Zhang (key20200714002512_b13-ol-0-0-7786) 2016; 7 Johnson (key20200714002512_b22-ol-0-0-7786) 2014; 47 Porter (key20200714002512_b1-ol-0-0-7786) 2010; 12 Pan (key20200714002512_b2-ol-0-0-7786) 2014; 32 Markel (key20200714002512_b9-ol-0-0-7786) 2002; 168 Kiriyama (key20200714002512_b5-ol-0-0-7786) 2014; 21 Ahn (key20200714002512_b28-ol-0-0-7786) 2013; 5 Hong (key20200714002512_b24-ol-0-0-7786) 2014; 13 Ashkenazi (key20200714002512_b16-ol-0-0-7786) 2016; 7 Peng (key20200714002512_b29-ol-0-0-7786) 2012; 72 Ortenberg (key20200714002512_b12-ol-0-0-7786) 2012; 11 Louis (key20200714002512_b21-ol-0-0-7786) 2007; 114 Markel (key20200714002512_b8-ol-0-0-7786) 2006; 177 Chen (key20200714002512_b11-ol-0-0-7786) 2011; 208 Li (key20200714002512_b14-ol-0-0-7786) 2013; 319 Markel (key20200714002512_b7-ol-0-0-7786) 2016; 34 Sharma (key20200714002512_b26-ol-0-0-7786) 2015; 348 Wang (key20200714002512_b4-ol-0-0-7786) 2014; 9 Hosomi (key20200714002512_b10-ol-0-0-7786) 2013; 43 Kim (key20200714002512_b27-ol-0-0-7786) 2016; 2016 Han (key20200714002512_b30-ol-0-0-7786) 2014; 33 Liu (key20200714002512_b19-ol-0-0-7786) 2016; 11 Huang (key20200714002512_b31-ol-0-0-7786) 2015; 517 Grayowen (key20200714002512_b15-ol-0-0-7786) 2006; 6 Platten (key20200714002512_b25-ol-0-0-7786) 2012; 1 Dupuis (key20200714002512_b6-ol-0-0-7786) 2015; 38 Feng (key20200714002512_b23-ol-0-0-7786) 2016; 58 Zhou (key20200714002512_b17-ol-0-0-7786) 2013; 111 Wainwright (key20200714002512_b20-ol-0-0-7786) 2014; 20 Stupp (key20200714002512_b3-ol-0-0-7786) 2005; 352 |
| References_xml | – volume: 5 start-page: 1379 year: 2013 ident: key20200714002512_b28-ol-0-0-7786 article-title: Immune-Checkpoint blockade and active immunotherapy for glioma publication-title: Cancers doi: 10.3390/cancers5041379 – volume: 47 start-page: 652 year: 2014 ident: key20200714002512_b22-ol-0-0-7786 article-title: The relationship between two performance scales: New York heart association classification and karnofsky performance status scale publication-title: J Pain Symptom Manage doi: 10.1016/j.jpainsymman.2013.05.006 – volume: 33 start-page: 245 year: 2014 ident: key20200714002512_b30-ol-0-0-7786 article-title: Tim-3 on peripheral CD4+ and CD8+ T cells is involved in the development of glioma publication-title: DNA Cell Biol doi: 10.1089/dna.2013.2306 – volume: 111 start-page: 257 year: 2013 ident: key20200714002512_b17-ol-0-0-7786 article-title: B7-H3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma publication-title: J Neurooncol doi: 10.1007/s11060-012-1021-2 – volume: 7 start-page: 30166 year: 2016 ident: key20200714002512_b16-ol-0-0-7786 article-title: SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells publication-title: Oncotarget doi: 10.18632/oncotarget.7379 – volume: 2016 start-page: 4683607 year: 2016 ident: key20200714002512_b27-ol-0-0-7786 article-title: Immune checkpoint modulators: An emerging antiglioma armamentarium publication-title: J Immunol Res doi: 10.1155/2016/4683607 – volume: 1 start-page: 99 year: 2012 ident: key20200714002512_b25-ol-0-0-7786 article-title: Shaping the glioma immune microenvironment through tryptophan metabolism publication-title: CNS Oncol doi: 10.2217/cns.12.6 – volume: 13 start-page: 132 year: 2014 ident: key20200714002512_b24-ol-0-0-7786 article-title: USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity publication-title: Mol Cancer doi: 10.1186/1476-4598-13-132 – volume: 72 start-page: 5209 year: 2012 ident: key20200714002512_b29-ol-0-0-7786 article-title: PD-1 blockade enhances T-cell migration to tumors by elevating IFN-γ inducible chemokines publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-1187 – volume: 517 start-page: 386 year: 2015 ident: key20200714002512_b31-ol-0-0-7786 article-title: CEACAM1 regulates TIM-3-mediated tolerance and exhaustion publication-title: Nature doi: 10.1038/nature13848 – volume: 6 start-page: 433 year: 2006 ident: key20200714002512_b15-ol-0-0-7786 article-title: CEACAM1: Contact-dependent control of immunity publication-title: Nat Rev Immunol doi: 10.1038/nri1864 – volume: 177 start-page: 6062 year: 2006 ident: key20200714002512_b8-ol-0-0-7786 article-title: Inhibition of human tumor-infiltrating lymphocyte effector functions by the homophilic carcinoembryonic cell adhesion molecule 1 interactions publication-title: J Immunol doi: 10.4049/jimmunol.177.9.6062 – volume: 43 start-page: 2473 year: 2013 ident: key20200714002512_b10-ol-0-0-7786 article-title: CEACAM1 on activated NK cells inhibits NKG2D-mediated cytolytic function and signaling publication-title: Eur J Immunol doi: 10.1002/eji.201242676 – volume: 11 start-page: 1300 year: 2012 ident: key20200714002512_b12-ol-0-0-7786 article-title: Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-11-0526 – volume: 7 start-page: 43604 year: 2016 ident: key20200714002512_b13-ol-0-0-7786 article-title: Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients publication-title: Oncotarget doi: 10.18632/oncotarget.9871 – volume: 114 start-page: 97 year: 2007 ident: key20200714002512_b21-ol-0-0-7786 article-title: The 2007 WHO classification of tumours of the central nervous system publication-title: Acta Neuropathol doi: 10.1007/s00401-007-0278-6 – volume: 58 start-page: 47 year: 2016 ident: key20200714002512_b23-ol-0-0-7786 article-title: Reduced expression of microRNA-497 is associated with greater angiogenesis and poor prognosis in human gliomas publication-title: Hum Pathol doi: 10.1016/j.humpath.2016.04.022 – volume: 9 start-page: e89991 year: 2014 ident: key20200714002512_b4-ol-0-0-7786 article-title: Neutrophils infiltration in the tongue squamous cell carcinoma and its correlation with CEACAM1 expression on tumor cells publication-title: PLoS One doi: 10.1371/journal.pone.0089991 – volume: 208 start-page: 2633 year: 2011 ident: key20200714002512_b11-ol-0-0-7786 article-title: CEACAM1 dampens antitumor immunity by down-regulating NKG2D ligand expression on tumor cells publication-title: J Exp Med doi: 10.1084/jem.20102575 – volume: 20 start-page: 5290 year: 2014 ident: key20200714002512_b20-ol-0-0-7786 article-title: Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4 and PD-L1 in mice with brain tumors publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-14-0514 – volume: 168 start-page: 2803 year: 2002 ident: key20200714002512_b9-ol-0-0-7786 article-title: CD66a interactions between human melanoma and NK cells: A novel class I MHC-independent inhibitory mechanism of cytotoxicity publication-title: J Immunol doi: 10.4049/jimmunol.168.6.2803 – volume: 319 start-page: 1061 year: 2013 ident: key20200714002512_b14-ol-0-0-7786 article-title: CEACAM1 regulates Fas-mediated apoptosis in Jurkat T-cells via its interaction with β-catenin publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2013.02.020 – volume: 12 start-page: 520 year: 2010 ident: key20200714002512_b1-ol-0-0-7786 article-title: Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology publication-title: Neuro-Oncology doi: 10.1093/neuonc/nop066 – volume: 38 start-page: 357 year: 2015 ident: key20200714002512_b6-ol-0-0-7786 article-title: The human antibody fragment DIATHIS1 specific for CEACAM1 enhances natural killer cell cytotoxicity against melanoma cell lines in vitro publication-title: J Immunother doi: 10.1097/CJI.0000000000000100 – volume: 32 start-page: 1957 year: 2014 ident: key20200714002512_b2-ol-0-0-7786 article-title: Immune responsive gene 1, a novel oncogene, increases the growth and tumorigenicity of glioma publication-title: Oncol Rep doi: 10.3892/or.2014.3474 – volume: 352 start-page: 987 year: 2005 ident: key20200714002512_b3-ol-0-0-7786 article-title: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma publication-title: N Engl J Med doi: 10.1056/NEJMoa043330 – volume: 18 start-page: 105 year: 2012 ident: key20200714002512_b18-ol-0-0-7786 article-title: Costimulatory protein 4IgB7H3 drives the malignant phenotype of glioblastoma by mediating immune escape and invasiveness publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-0880 – volume: 34 year: 2016 ident: key20200714002512_b7-ol-0-0-7786 article-title: Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity publication-title: J Clin Oncol doi: 10.1200/JCO.2016.34.15_suppl.3044 – volume: 11 start-page: 1829 year: 2016 ident: key20200714002512_b19-ol-0-0-7786 article-title: Expression of the galectin-9-Tim-3 pathway in glioma tissues is associated with the clinical manifestations of glioma publication-title: Oncol Lett doi: 10.3892/ol.2016.4142 – volume: 21 start-page: S505 year: 2014 ident: key20200714002512_b5-ol-0-0-7786 article-title: CEACAM1 long cytoplasmic domain isoform is associated with invasion and recurrence of hepatocellular carcinoma publication-title: Ann Surg Oncol doi: 10.1245/s10434-013-3460-1 – volume: 348 start-page: 56 year: 2015 ident: key20200714002512_b26-ol-0-0-7786 article-title: The future of immune checkpoint therapy publication-title: Science doi: 10.1126/science.aaa8172 |
| SSID | ssj0000561886 |
| Score | 2.1602175 |
| Snippet | Glioma, the most prevalent primary tumor of the central nervous system, is known to evade immune surveillance and escape immune attacks by inducing... |
| SourceID | pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 3496 |
| SubjectTerms | Antigens Biological products Biomarkers Brain cancer Cancer research Cancer treatment Carcinoembryonic antigen Care and treatment Cell adhesion & migration Cell adhesion molecules Cytokines Development and progression Diagnosis Glioma Gliomas Health aspects Immunoglobulins Immunology Immunotherapy Ligands Lymphocytes Medical prognosis Oncology Physiological aspects Studies Tumors |
| Title | Abnormal expression of circulating and tumor-infiltrating carcinoembryonic antigen-related cell adhesion molecule 1 in patients with glioma |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29467871 https://www.proquest.com/docview/2014189603 https://www.proquest.com/docview/2007420942 https://pubmed.ncbi.nlm.nih.gov/PMC5796289 |
| Volume | 15 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3daxQxEA_agvgi1s_VWiMoPkjs7WY_n-RaWopgEbFwbyHJJu3CXrbe7YH-Df7TzmRz266gr5e5u93JTPKbyeQ3hLzVMi54nifMzrhiaWlnTMqsZCmXWaWSIpa1r_I9z88u0s-LbBESbutQVrldE_1CXXcac-QQpMdpXALe5p-ufzDsGoWnq6GFxl2y66nLwJ6LRTHmWBAdl77ZI5hdwrD2cKh9h106Oezw5CEuPyKD2mRX-nttvrU5TQsnb-1Epw_JgwAh6XyY8z1yx7hH5N6XcEj-mPyeK4dItKXmZyhzdbSzVDcr7Zt1uUsqXU37zbJbMbCwpvXcufCxxs5CrjNLtfqFnLkg1yNdJ_NXXkxNMc9PZX1l_I8uh966hsa0cTRQtK4p5nbpZdt0S_mEXJyefD8-Y6HnAtPgnT1TNSCmzOjCJICciipP6jxXM6NTpQD9VZXmOuPWqDy3VtWZLPI0Bn1IJeuisjF_SnZc58xzQq0BpQNakAoghIVIJFYlgOTKcsPBbpKIfNjqXOhASI59MVoBgQnOkOhagTMkcIYi8m6Uvh6IOP4h9xqnTwzXSEf_FXMsowUTyXhE3nsJ9GD4Py3DRQR4auTCmkjuTyTB8_R0eGsiInj-WtzYaUTejMP4Taxmc6bboAxmJCCwBh08GyxqfKekgq0LotiIFBNbGwWQD3w64porzwuO14ohfn7x_8d6Se6jsoY6un2y06825hUAq14deO85ILtHJ-dfv_0BVsAmcQ |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9QwEB6VrQRcKt6kFGokKg7IsHknB4QWaLWl7QqhVuot2I7TRso6ZTcr6G_gv_AbmcmLBgluva5ns1nPePyNPfMNwAsl7NANAodnY1dyL8rGXAg_4p4r_Fg6oS3SOst3FkxPvE-n_uka_OpqYSitsvOJtaNOS0Vn5Bik254dId52311849Q1im5XuxYajVkc6MvvGLIt3-5_RP3uOM7e7vGHKW-7CnCF9ldxmSIm8LUKtYPYIIwDJw0COdbKkxLxTRwrV_lupmUQZJlMfREGnp0qLaRIwzizXXzuDVj3qKJ1BOvvd2efv_SnOoTHo7q9JBq6wynbscm2R1zgvCnprsOOXhNn22Af_Hs3uLIdDlM1r-x9e3dgowWtbNJY2V1Y0-Ye3Dxqr-Xvw8-JNIR9C6Z_tIm1hpUZU_lC1e3BzBkTJmXVal4uONp0XtRsvfixol5GptRzubgkll6Uq4gglNdFNjpldLPARHqu64fOm26-mtksN6wlhV0yOk1mZ0VezsUDOLkWfTyEkSmNfgws0zjpiE-ERNCSYexjywhheZy52kVLdSx41c15oloKdOrEUSQYCpGGkrJISEMJaciCnV76oqH--IfcNqkvaQpXe4-RTChxN0aE6lrwspYgn4G_p0Rb-oBvTexbA8mtgSSudTUc7kwkaX3NMvmzMix43g_TNyl_zuhyRTJ0BoKhPM7Bo8ai-v_kxLhZYtxsQTiwtV6AGMiHIyY_r5nIqZAZI_bN_7_WNtyaHh8dJof7s4MncJsmrsni24JRtVjppwjrKvmsXUsMvl738v0NIKNk5A |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Jb9NAFB6VIlVcEHsNhQ4SFQc0NPZ4PSAUUaKWQsWBSrmZWVtLzrgkjqC_gX_Er-M9b9RIcOs18-I487bvzbyFkBdK-AmP44DZCZcsTO2ECRGlLOQiymSQ-EI3Wb4n8eFp-GEezTfIr74WBtMqe5vYGGpdKTwjhyDdD_0U8Dbft11axOeD2duLbwwnSOFNaz9OoxWRY3P5HcK31ZujA-D1XhDM3n95d8i6CQNMgSzWTGrAB5FRiQkAJyRZHOg4lhOjQikB62SZ4iri1sg4tlbqSCRx6GtlhBQ6yazP4bk3yM2EA6oCXUrmyXC-g8g8bQZNgsgHDPMe27x7QAjBfoW3Hn76Gru3jTzi337himMcJ21e8YKzO-R2B1_ptJW3u2TDuHtk61N3QX-f_JxKhyi4pOZHl2LraGWpKpaqGRTmzqhwmtbrRbVkIN1F2fTthY8VTjVylVnI5SX26wW6GluFsqbcxmiKdwxU6HPTPHTRzvU11KeFo1172BXFc2V6VhbVQjwgp9fCjYdk01XObBNqDWw6IBUhAb5YiIJ8mQJAzyw3HGQ28Mirfs9z1TVDx5kcZQ5BEXIor8ocOZQjhzyyN1BftE1A_kG3i-zL2xLWwXbkU0zhzQCrco-8bCjQesDvKdEVQcBbYx-uEeXOiBK0Xo2XexHJO6uzyv_oiEeeD8v4Tcykc6ZaIw2ehkBQD3vwqJWo4T8FGbhNiKA9koxkbSDAXuTjFVecNz3JsaQZYvfH_3-tXbIFSpt_PDo5fkJu4b616Xw7ZLNers1TwHe1fNYoEiVfr1tzfwNeHGer |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Abnormal+expression+of+circulating+and+tumor-infiltrating+carcinoembryonic+antigen-related+cell+adhesion+molecule+1+in+patients+with+glioma&rft.jtitle=Oncology+letters&rft.au=Li%2C+Jinhu&rft.au=Liu%2C+Xiaodong&rft.au=Duan%2C+Yijun&rft.au=Wang%2C+Hongqin&rft.date=2018-03-01&rft.pub=D.A.+Spandidos&rft.issn=1792-1074&rft.eissn=1792-1082&rft.volume=15&rft.issue=3&rft.spage=3496&rft.epage=3503&rft_id=info:doi/10.3892%2Fol.2018.7786&rft_id=info%3Apmid%2F29467871&rft.externalDocID=PMC5796289 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1792-1074&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1792-1074&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1792-1074&client=summon |